EUCTR2012-001938-34-ES进行中（未招募）不适用
Biological standardization of Platanus acerifolia allergen extract todetermine the biological activity in HEP units.
aboratorios Leti, S.L.Unipersonal0 个研究点开始时间: 2012年8月23日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Subject has provided written informed consent, appropriately signed and dated by the subject (or legal representative, if applicable).
- •-Subject can be male or female of any race and ethnic group.
- •-Age > and =18 years and < and =60 years at the study inclusion day.
- •-Positive skin prick test with a standardized commercially available preparation of Platanus acerifolia allergen extract. The skin prick test will be considered positive if the test results in a wheal major diameter of at least 3 mm or an area at least 7 mm2. Positive skin prick test results are valid if performed within one year prior to the inclusion of the subject in the study
- •-A positive test for specific IgE to Platanus acerifolia (CAP-RAST major or equal to 2). IgE results are valid if performed within oneyear prior to the inclusion of the subject in the study.
- •-Allergic symptoms during the pollen season of Platanus acerifolia.
- •-Medical history positive allergy inhalation (rhinitis and /or rhinoconjunctivitis and/or asthma) from Platanus acerifolia.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Immunotherapy in the past 5 years with an allergen preparation known to interfere with the allergen to be tested due to a high degree of cross-reactivity (for example: other species of Platanus: Platanus orientalis, Platanus occidentalis).
- •-Use of drugs that may interfere with the skin reactions (e.g., antihistamines). See Appendix 1 of the protocol
- •-Treatment with any of the following medications: oral tricyclic or tetracyclic antidepressants or IMAOs, beta-blockers, chronic use of corticosteroids or use of oral or parenteral corticosteroids in repeated and intermittent patterns (10 mg/daily of prednisone or equivalent).
- •-Women who are pregnant or period of breastfeeding and women with a pregnancy test positive during the visit 2, prior to the prick test.
- •-Dermographism affecting the skin area at the test site at either study visit.
- •-Atopic dermatitis affecting the skin area at the test site at either study visit.
- •-Urticaria affecting the skin area at the test site at either study visit.
- •- Diseases of the immune system relevant clinically, both autoimmune and immunodeficiencies.
- •-Serious diseases not controlled that may increase the risk for the safety of the subjects involved in this study, including, but not limited to the following: heart failure, uncontrolled or severe respiratory diseases, endocrine diseases, clinically relevant kidney or liver diseases or hematological diseases.
- •-Participation in any other clinical trial within 30 days (or 5 times the biological half-life of the research of the study product, whichever is longer) prior to the inclusion of the subject in this clinical trial.
- •-Patients with diseases or conditions that limit the use of adrenaline (heart disease, severe hypertension, ..)
- •-Severe psychiatric, psychological or neurological disorders
- •-Abuse of alcohol, drugs or medicines in the previous year.
研究者
相似试验
已完成
2 期
Biological Standardization of Platanus Acerifolia Allergen ExtractAllergy to Platanus AcerifoliaNCT01739322Laboratorios Leti, S.L.36
进行中（未招募）
不适用
To determine the minimum amount of Poa pratensis allergen extract producing a positive skin reaction.Allergy to Poa pratensis.MedDRA version: 14.0Level: LLTClassification code 10036019Term: Pollen allergySystem Organ Class: 10021428 - Immune system disordersEUCTR2010-023950-35-ESaboratorios Leti, S.L.Unipersonal
进行中（未招募）
不适用
To determine the minimum amount of Alternaria alternata allergenextract producing a positive skin reaction.Allergy to Alternaria alternataEUCTR2013-001308-13-ESABORATORIOS LETI S.L.
进行中（未招募）
不适用
To determine the minimum amount of Artemisia vulgaris allergen extract producing a positive skin reaction.Allergy to Artermisia vulgarisMedDRA version: 14.1Level: LLTClassification code 10036019Term: Pollen allergySystem Organ Class: 100000004870EUCTR2013-001310-15-ESABORATORIOS LETI, S.L.
进行中（未招募）
不适用
Application of different concentrations of ragwood-allergen-solution (Ambrosia elatior allergen extract) as Prick-Test to define a standard with certain specificationsEUCTR2011-002096-42-DEETI Pharma GmbH